Rudolph Willis, MD
Family Practice · Irvington, NJNPI 1104887819
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 25.7% of the total. Reporting peaked in 2023 at $1,236 and has fallen 67.2% since, to $405 in 2025. Among family practice clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$885
- Lilly USA, LLC$504
- Sanofi-aventis U.S. LLC$502
- Kowa Pharmaceuticals America, Inc.$378
- Merck$347
- plus $872 from 12 others
What the payments were for
- Food & beverage$4,681100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $1,204 |
| AstraZeneca | 16 | $885 |
| Lilly USA, LLC | 23 | $504 |
| Sanofi-aventis U.S. LLC | 16 | $502 |
| Kowa Pharmaceuticals America, Inc. | 23 | $378 |
| Merck | 28 | $347 |
| Mannkind Corporation | 2 | $143 |
| GSK | 2 | $139 |
| Bayer | 1 | $122 |
| Boehringer Ingelheim | 8 | $115 |
| Orexo US, Inc. | 5 | $93 |
| Johnson & Johnson | 1 | $75 |
| Indivior Inc. | 2 | $52 |
| Exact Sciences | 2 | $44 |
| Amgen | 2 | $31 |
| Pfizer | 1 | $30 |
| Gilead | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,692 in reported general payments places this provider in the 95th percentile of 248 family practice providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $101,685 |
| RybelsusSemaglutide | 39 | $61,175 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 62 | $53,941 |
| FarxigaDapagliflozin Propanediol | 53 | $49,479 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 31 | $43,404 |
| JardianceEmpagliflozin | 39 | $36,022 |
| MounjaroTirzepatide | 31 | $32,944 |
| Xigduo XrDapaglifloz Propaned/Metformin | 42 | $26,382 |
| XareltoRivaroxaban | 19 | $14,734 |
| EliquisApixaban | 11 | $12,877 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,801 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 172 | $9,684 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,017 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $7,603 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 53 | $6,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,204 | $162,860114 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $115 | $79,42670 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $502 | $53,94162 claims |
| AstraZenecaFarxiga | $885 | $49,47953 claims |
| Lilly USA, LLCMounjaro | $504 | $32,94431 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $139 | $15,89529 claims |
| Johnson & JohnsonXarelto | $75 | $14,73419 claims |
| PfizerEliquis | $30 | $12,87711 claims |
| Orexo US, Inc.Zubsolv | $93 | $6,34313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 family practice providers in New Jersey.
Other family practice in Irvington
- Alex GuslerSomerset$6K
- Luis JaramilloWest New York$6K
- Robert LukendaCranford$5K
- Mihir PatelBrick$5K
- Omar HassanienPassaic$3K
- Robert BockWayne$2K
- Thayalan CumarasamyBurlington$2K
- Francis KielarButler$2K
- Ryan TourtellotBrick$215
- Sarah LevyBoonton$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.